Carlayne Jackson, MD
Neurology · San Antonio, TXNPI 1083620967
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (50.4%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 9 manufacturers reported payments, led by Tanabe Pharma America, Inc. at 52.9% of the total. Reporting peaked in 2019 at $61,609 and has fallen 95.5% since, to $2,778 in 2023. Among neurology clinicians in TX with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 102 payments — averaging $757.00 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Tanabe Pharma America, Inc.$41K
- CSL Behring$14K
- Mitsubishi Tanabe Pharma Development America, Inc.$7K
- AstraZeneca$6K
- Avanir Pharmaceuticals, Inc.$4K
- Mallinckrodt Enterprises LLC$3K
- plus $866 from 3 others
Across 15 payments — averaging $6751.24 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- UCB SA$30K
- Biohaven Pharmaceutical Holding Company Ltd.$27K
- Mitsubishi Tanabe Pharma Development America, Inc.$20K
- Catalyst Pharmaceuticals, Inc.$16K
- Tanabe Pharma America, Inc.$9K
What the payments were for
- Consulting fees$38,88650%
- Speaking & faculty fees$30,21039%
- Travel & lodging$5,6557%
- Food & beverage$2,3803%
- Education$830%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Tanabe Pharma America, Inc. | 50 | $40,865 |
| CSL Behring | 15 | $14,264 |
| Mitsubishi Tanabe Pharma Development America, Inc. | 6 | $7,425 |
| AstraZeneca | 16 | $6,358 |
| Avanir Pharmaceuticals, Inc. | 5 | $3,949 |
| Mallinckrodt Enterprises LLC | 3 | $3,488 |
| MDD US Operations, LLC | 1 | $500 |
| Strongbridge US Inc. | 5 | $295 |
| Grifols Shared Services North America, Inc. | 1 | $71 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$77,214 in reported general payments places this provider in the 90th percentile of 1,246 neurology providers in Texas.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Radicava OrsEdaravone | 181 | $2,512,612 |
| FirdapseAmifampridine Phosphate | 31 | $1,533,844 |
| GammakedImmune Globul G/Gly/Iga Avg 46 | 38 | $563,659 |
| RelyvrioSod Phenylbutyrat/Taurursodiol | 22 | $268,724 |
| PrivigenImmun Glob G(Igg)/Pro/Iga 0-50 | 26 | $203,404 |
| RadicavaEdaravone | 16 | $203,078 |
| Gamunex-CImmune Globul G/Gly/Iga Avg 46 | 13 | $134,309 |
| NuedextaDextromethorphan Hbr/Quinidine | 73 | $133,320 |
| Riluzole | 58 | $9,506 |
| Mycophenolate Mofetil | 39 | $8,041 |
| Pyridostigmine Bromide | 52 | $4,992 |
| Glycopyrrolate | 78 | $4,390 |
| Baclofen | 36 | $1,756 |
| Atropine Sulfate | 13 | $1,363 |
| Gabapentin | 30 | $1,078 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| CSL BehringPrivigen | $14,264 | $203,40426 claims |
| Avanir Pharmaceuticals, Inc.Nuedexta | $3,949 | $133,32073 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 1,246 neurology providers in Texas.
Other neurology in San Antonio
- Ann BassSan Antonio$1.7M
- Santiago RestrepoSan Antonio$532K
- Juan Ramirez CastanedaSan Antonio$456K
- Eleni VaouSan Antonio$236K
- Eric PappertSan Antonio$166K
- Arash SalardiniSan Antonio$125K
- William OndoHouston$1.4M
- Nirav PavasiaDallas$1.4M
- Mirla AvilaLubbock$1.3M
- Michael SoileauGeorgetown$1.2M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.